InvestorsHub Logo
Followers 14
Posts 2307
Boards Moderated 0
Alias Born 01/02/2003

Re: None

Monday, 06/14/2021 7:11:32 AM

Monday, June 14, 2021 7:11:32 AM

Post# of 462688
“Completed enrollment”...great NEWS tidbit hidden in the PR today.

From the PR -

This independent paper highlights the understanding of the relevance of utilizing sigma-1 receptor activation as compensatory mechanism to chronic CNS diseases, currently tested in late-stage placebo-controlled ANAVEX®2-73 Phase 2b/3 clinical Alzheimer's disease study, which recently completed enrollment, as well as in Parkinson’s disease dementia (ANAVEX2-73-PDD-001) and ongoing Rett syndrome program (ANAVEX2-73-RS-001/002/003)”, said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex.

-vg_future
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News